Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 22-30 , January 2003

Epidermal growth factor family receptors and inhibitors: Radiation response modulators

References 

  1. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;4(suppl):S3–S8
  2. Baselga J. The EGFR as a target for anticancer therapy—Focus on cetuximab. Eur J Cancer. 2001;4(suppl):S16–S22
  3. Klapper LN, Waterman H, Sela M, et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cb1 and enhancing ubiquitination of HER-2. Cancer Res. 2000;60:3384–3388
  4. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958–2970
  5. Barker FG, Simmons ML, Chang SM, et al.  EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51:410–418
  6. Gupta AK, McKenna WG, Weber CN, et al.  Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002;8:885–892
  7. Sheridan MT, O'Dwyer T, Seymour CB, et al.  Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5:180–186
  8. FitzGerald TJ, Henault S, Sakakeeny M, et al.  Expression of transfected recombinant oncogenes increases radiation resistance of clonal hematopoietic and fibroblast cell lines selectively at clinical low dose rate. Radiat Res. 1990;122:44–52
  9. Balaban N, Moni J, Shannon M, et al.  The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta. 1996;1314:147–156
  10. Wollman R, Yahalom J, Maxy R, et al.  Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 1994;30:91–98
  11. Kwok TT, Sutherland RM. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer. 1991;64:251–254
  12. Bonner JA, Maihle NJ, Folven BR, et al.  The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys. 1994;29:243–247
  13. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15:1191–1197
  14. Todd DG, Mikkelsen RB, Rorrer WK, et al.  Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and ERBB- 3, and changes of intracellular calcium in A431 human squamous carcinoma cells. J Recept Signal Transduct Res. 1999;19:885–908
  15. Carter S, Auer KL, Reardon DB, et al.  Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene. 1998;16:2787–2796
  16. Schmidt-Ullrich RK, Valerie KC, Chan W, et al.  Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys. 1994;29:813–819
  17. Zhou H, Dy R, Sartor C. A New Series of Radioresistant Breast Cancer Cell Lines Demonstrate Frequent Alterations in EGFR Signaling. Ventura, CA: Gordon Research Conference,; January 28-February 2, 2001;
  18. Haffty BG, Brown F, Carter D, et al.  Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. Int J Radiat Oncol Biol Phys. 1996;35:751–757
  19. Pirollo KF, Tong YA, Villegas Z, et al.  Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation- resistant phenotype. Radiat Res. 1993;135:234–243
  20. Pietras RJ, Poen JC, Gallardo D, et al.  Monoclonal antibody to HER-2/neureceptor modulates repair of radiation- induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 2001;59:1347–1355
  21. Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol. 2001;11:281–289
  22. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001;49:427–433
  23. Nasu S, Ang KK, Fan Z, et al.  C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 2001;51:474–477
  24. Raben D, Buchsbaum D, Gillespie Y, et al.  Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. In: American Association for Cancer Research 90th Annual Meeting A1224. Philadelphia, PA: Cancer Research; 1999;
  25. Helfrich B, Phistry M, Chan D, et al.  ZD1839 (Iressa), a Selective EGFR-TKI, Enhances Radiation and Chemotherapy Cytotoxicity in EGFR Positive Human Non-Small Cell Lung Cancer Cells (NSCLC) in Vitro. In: Molecular Biology and New Treatment Strategies: Cancer Research in the 21st Century, Maui, HI,. 2001;p. B10
  26. Williams K, Telfer B, Stratford I, et al.  Combination of ZD1839 (Iressa), and EGFR-TKI, and radiotherapy increases antitumor efficacy in a human colon cancer xenograft. In: American Association for Cancer Research 92nd Annual Meeting, New Orleans, LA, Cancer Research, A3480. 2001;
  27. She Y, Lee F, Haimovitz-Friedman A, et al.  The selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) enhances radiation sensitivity of human tumor xenografts in nude mice. In: American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, Cancer Research, A3894,. 2002;
  28. Stea B, Falsey R, Carey S, et al.  Growth inhibition and radiosensitization of glioblastoma multiforme by the tyrosine kinase inhibitor ZD1839 (Iressa). In: American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, Cancer Research, A3899,. 2002;
  29. Anido J, Albanell J, Rojo F, et al.  ZD1839 (Iressa), a specific epidermal growth factor receptor tyrosine kinase inhibitor, induces the formatin of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2 overexpressing breast cancer cells. In: American Association for Cancer Research 93rd Annual Meeting, San Francisco, CA, Cancer Research, A3881,. 2002;
  30. Christensen JG, Schreck RE, Chan E, et al.  High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res. 2001;7:4230–4238
  31. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys. 2000;48:1519–1528
  32. Rusnak DW, Affleck K, Cockerill SG, et al.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001;61:7196–7203
  33. Contessa JN, Reardon DB, Todd D, et al.  The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res. 1999;5:405–411
  34. Lammering G, Hewit TH, Hawkins WT, et al.  Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 2001;93:921–929
  35. O'Rourke DM, Kao GD, Singh N, et al.  Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. P Natl Acad Sci. 1998;95:10842–10847
  36. Bonner J, Ezekiel M, Robert F, et al.  Continued response following treatment with IMC-C225, and EGFr MoAb combined with RT in advanced head and neck malignancies. In: American Society of Clinical Oncology 36th Annual Meeting 5F. New Orleans, LA: Journal of Clinical Oncology; 2000;
  37. Raben D, Helfrich BA, Chan D, et al.  ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002;29:37–46
  38. Seidman A, Hudis C, Pierri MK, et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  39. Early Breast Cancer Trialists' Collaborative Group . Favourable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet. 2000;355:1757–1770
  40. Rohrbach S, Yan X, Weinberg EO, et al.  Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation. 1999;100:407–412
  41. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell. 2000;103:239–252
  42. Canman CE, Kastan MB. Signal transduction. Three paths to stress relief. Nature. 1996;384:213–214
  43. Verheij M, Bose R, Lin XH, et al.  Requirement for ceramide-initiated SAPK/JNK signalling in stress- induced apoptosis. Nature. 1996;380:75–79
  44. Ruiter GA, Zerp SF, Bartelink H, et al.  Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res. 1999;59:2457–2463
  45. Reardon DB, Contessa JN, Mikkelsen RB, et al.  Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene. 1999;18:4756–4766
  46. Brognard J, Clark AS, Ni Y, et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986–3997
  47. Grana T, Rusyn E, Zhou H, et al.  Ras mediates radioresistance through both PI3-K-dependent and Raf-dependent but MEK-independent signaling pathways. Cancer Res. 2002;62:4142–4150
  48. Grana T, Zhou H, Sartor C, et al.  Ras-mediated radiation resistance via autocrine pathways. In: Radiation Research Society 49th Annual Meeting, Reno, NV,. 2002;p. P29–P288
  49. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241–246
  50. Pianetti S, Arsura M, Romieu-Mourez R, et al.  Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene. 2001;20:1287–1299
  51. Zhou BP, Hu MC, Miller SA, et al.  HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem. 2000;275:8027–8031
  52. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935–1940
  53. Milas L, Mason K, Hunter N, et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701–708
  54. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6:2166–2174
  55. Ciardiello F, Caputo R, Bianco R, et al.  Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7:1459–1465

☆ Supported in part by 1-K08-CA83753, National Institutes of Health.

☆☆ Address reprint requests to Carolyn I. Sartor, MD, UNC Hospitals, Department of Radiation Oncology, NC Clinical Cancer Center, 101 Manning Drive, Chapel Hill, NC 27514.

PII: S1053-4296(03)50005-4

doi: 10.1053/srao.2003.50003

Seminars in Radiation Oncology
Volume 13, Issue 1 , Pages 22-30 , January 2003

Article Tools

* Image Usage & Resolution